

Shubik Yuri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6575972/shubik-yuri-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

9,918
citations

13
h-index

23
g-index

23
ext. papers

11,574
ext. citations

7.3
avg, IF

5.86
L-index

#	Paper	IF	Citations
23	Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 668-673	0.5	1
22	Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 193-199	0.5	7
21	Management of atrial fibrillation in Russia: real clinical practice and current clinical guidelines. <i>Journal of Arrhythmology</i> , 2021 , 28, 55-63	0.3	3
20	International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). <i>Thrombosis Journal</i> , 2019 , 17, 7	5.6	7
19	Interatrial block in prediction of all-cause mortality after first-ever ischemic stroke. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 37	2.3	11
18	Lethal immunoglobulins: Autoantibodies and sudden cardiac death. <i>Autoimmunity Reviews</i> , 2019 , 18, 415-425	13.6	19
17	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). <i>American Journal of Cardiology</i> , 2018 , 122, 578-583	3	8
16	Non-permanent atrial fibrillation and oral anticoagulant therapy are related to survival during 10years after first-ever ischemic stroke. <i>International Journal of Cardiology</i> , 2017 , 232, 134-139	3.2	3
15	Atrial time and voltage dispersion are both needed to predict new-onset atrial fibrillation in ischemic stroke patients. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 200	2.3	6
14	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016 , 5, e002197	6	94
13	Predictors of new onset atrial fibrillation during 10-year follow-up after first-ever ischemic stroke. <i>International Journal of Cardiology</i> , 2015 , 199, 248-52	3.2	16
12	Documentation of atrial fibrillation prior to first-ever ischemic stroke. <i>Acta Neurologica Scandinavica</i> , 2014 , 129, 412-9	3.8	7
11	Atrial fibrillation in patients with ischaemic stroke in the Swedish national patient registers: how much do we miss?. <i>Europace</i> , 2014 , 16, 1714-9	3.9	13
10	Dronedarone in high-risk permanent atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 2268-76	36.2	438
9	Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. <i>Circulation</i> , 2011 , 124, 2649-60	16.7	35
8	Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 725-31	15.1	416
7	A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. <i>Chest</i> , 2010 , 138, 1093-100	5.3	2947

6	Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. <i>Chest</i> , 2010 , 137, 263-72	5.3	4353
5	Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. <i>European Heart Journal</i> , 2008 , 29, 1181-9	9.5	201
4	Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 572-7	15.1	301
3	Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. <i>European Heart Journal</i> , 2006 , 27, 2969-74	9.5	130
2	Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2006 , 27, 3018-26	9.5	289
1	Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2005 , 26, 2422-34	9.5	613